Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
December 21st 2023Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
Liquid Biopsy May Predict T-DXd Activity in HER2+ Metastatic Breast
December 13th 2023It is important to look at different assays beyond immunohistochemistry to better gather information and potentially predict the activity of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer, says Paolo Tarantino, MD.
Ribociclib Combo Yields iDFS Improvement in HR+/HER2– Breast Cancer
December 9th 2023Combining ribociclib with nonsteroidal aromatase inhibitor treatment also produces relapse-free survival and distant disease-free survival benefits in patients with HR-positive, HER2-negative early-stage breast cancer.
Alpha-Lactalbumin Vaccine May be ‘Exciting’ Option for Preventing/Treating TNBC
December 9th 2023More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.
Profiling Tests May Predict Chemo Efficacy in Early-Stage Breast Cancer
December 8th 2023Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.
Dato-DXd Improves PFS Vs Chemo in HR+/HER2– Metastatic Breast Cancer
December 8th 2023Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.
T-DXd Shows Early OS Benefit in HER2+/HER2-Low Breast Cancer and Leptomeningeal Carcinomatosis
December 7th 2023The DEBBRAH trial met its primary endpoint of overall survival in a cohort of patients with HER2-positive or HER2-low advanced breast cancer and leptomeningeal carcinomatosis with positive cerebrospinal fluid cytology.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC
December 7th 2023Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.
Pembrolizumab Combo Yields Significant pCR in High-Risk ER+ Breast Cancer
December 7th 2023The pembrolizumab-based regimen in the phase 3 KEYNOTE-756 trial produces a larger pathologic complete response benefit in patients with node-positive disease and higher PD-L1 expression, according to Joyce O’Shaughnessy, MD.
ctDNA Confers Recurrence Risk After Abemaciclib Combo in Breast Cancer
December 6th 2023A future planned analysis of the monarchE trial may further define how circulating tumor DNA dynamics can help identify patients with hormone receptor–positive HER2-negative breast cancer who are at high risk of recurrence.
Capivasertib Combo Yields HRQOL Improvements in HR+/HER2– Breast Cancer
December 6th 2023Combining capivasertib with fulvestrant improves time to deterioration compared with placebo plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer in the CAPItello-291 trial.